Chimerix, the North Carolina-based antiviral drug maker, secured a Series F funding for about $45 million, peHUB has learned from multiple sources. Management and directors at the company met today at the company’s headquarters and the fundraise is expected to be announced next week.
Several of Chimerix’s prior investors joined in the latest funding round, and two new VCs are on board as well, one of our sources said.
The funding increases Chimerix’s aggregate funding well past $100 million. Funding will be used as the company continues to push an antiviral drug through FDA approval procedures.
Last year, Chimerix shuffled management, putting President Kenneth Moch into the CEO role and shifting Chairman of the Board George Painter to the position of chief scientific officer. Painter had led the company since its founding in 2002.
Prior rounds of funding came from investors including Frazier Technology Ventures, Sanderling Ventures, Asset Management Company, Canaan Partners and Asset Management Company, totaling more than $27 million, according to Techcrunch. Other reports indicate the company bagged another $23 million in funding from private investors. Federal funding pumped an aggregate $38 million more, peHUB’s sources confirm.
The company did not have a formal response.